Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG

(EUZ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eckert & Ziegler Strahlen und Medizintechnik : & Ziegler Extends Gallium-68 Generator Portfolio in the United States

09/03/2021 | 09:01am EDT

Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Master File (DMF) to the U.S. Food and Drug Administration for GalliaPharm®. Their proprietary Ge-68/Ga-68 generator from now on will additionally be available in sizes of up to 100 mCi with a shelf-life of 12 months or for a maximum of 700 elutions. Gallium-68 from GalliaPharm® is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).

“With the development of generators with higher Ge-68 activity and the amendment of our DMF, we are responding to the increasing demand for Ga-68 based diagnostics in the United States,” explained Dr Harald Hasselmann, Eckert & Ziegler Executive Director and responsible for the Medical segment. “The soon to be available preparations for imaging of prostate cancer as well as upcoming novel Ga-68 drugs and their theranostic pair, mostly labeled with Lu-177, allow Eckert & Ziegler to strongly support the trend towards higher activity generators and we are currently working to provide comprehensive solutions to the healthcare providers and their patients.”

“Higher activity GalliaPharm® generators will enable nuclear medicine institutions and radiopharmacies across the United States to prepare their Ga-68 PET imaging products with the same flexibility as they are used to, while being able to offer the procedures to a greater number of patients and with an expanded service area,“ added Jay Simon, General Manager of Eckert & Ziegler Radiopharma, Inc. in Wilmington, MA. “Users can obtain additional doses from a single generator elution and are at the same time able to significantly increase the number of daily elutions. Both will contribute to enhanced medical care and assure the supply to American patients.”

GalliaPharm® is mainly used in combination with tracer kits for diagnosis of neuroendocrine tumors and prostate cancer. Gallium generators offer a low-cost alternative for the radiolabeling of biomolecules with Gallium-68 in PET, an imaging examination method used to detect the presence or absence of diseased tissue. PET imaging is primarily used in the diagnosis of cancer, cardiology or neurology. Radioisotopes such as Fluorine-18 can be used alternatively but require investments of millions of dollars in large-scale equipment (cyclotrons). The Ge-68/Ga-68 generator on the other hand, is an easily transportable, small system that is much more cost-efficient, leading to cost reductions for nuclear medicine providers while increasing flexibility.

About Eckert & Ziegler Radiopharma GmbH

Eckert & Ziegler Radiopharma GmbH is a wholly owned subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG and part of Eckert & Ziegler’s Medical business segment. The company is specialized in the field of nuclear medicine and molecular imaging, providing radiopharmaceuticals and radiochemicals for diagnosis, treatment and research purposes. With GalliaPharm® and Yttriga, sterile Yttrium-90 chloride solution, Radiopharma GmbH provides two core pharmaceutical products for diagnosis and therapy. Moreover, the company offers development and contract manufacturing services.


ę Business Wire 2021
All news about ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
10/11ECKERT & ZIEGLER STRAHLEN UND MEDIZI : & Ziegler Acquires 53,000 Square Feet Facility for ..
PU
10/11ECKERT & ZIEGLER STRAHLEN UND MEDIZI : & Ziegler Acquires 53,000 Square Feet Facility for ..
EQ
10/11PRESS RELEASE : Eckert & Ziegler Acquires 53,000 Square Feet Facility for Expansion of Con..
DJ
09/30Eckert & Ziegler Strahlen- und Medizintechnik AG english
DJ
09/28ECKERT & ZIEGLER : Hauck & Aufhauser reaffirms its Buy rating
MD
09/28ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Hauck & Aufhäuser
PU
09/27ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Nantes University Hospital Doses First Patients wit..
PU
09/27ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Nantes University Hospital Doses First Patients wit..
EQ
09/27PRESS RELEASE : Nantes University Hospital Doses First Patients with Eckert & Ziegler's No..
DJ
09/23ECKERT & ZIEGLER STRAHLEN- UND MEDIZ : Release according to Article 40, Section 1 of the W..
DJ
More news
Analyst Recommendations on ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
More recommendations
Financials
Sales 2021 180 M 208 M 208 M
Net income 2021 26,9 M 31,2 M 31,2 M
Net cash 2021 96,9 M 112 M 112 M
P/E ratio 2021 97,3x
Yield 2021 0,35%
Capitalization 2 645 M 3 066 M 3 070 M
EV / Sales 2021 14,2x
EV / Sales 2022 11,2x
Nbr of Employees 814
Free-Float 67,0%
Chart ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Duration : Period :
Eckert & Ziegler Strahlen- und Medizintechnik AG Technical Analysis Chart | EUZ | DE0005659700 | MarketScreener
Technical analysis trends ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 127,50 €
Average target price 172,00 €
Spread / Average Target 34,9%
EPS Revisions
Managers and Directors
Andreas Eckert Chairman-Executive Board
Wolfgang Maennig Chairman-Supervisory Board
Helmut Grothe Vice Chairman-Supervisory Board
Albert Rupprecht Member-Supervisory Board
Edgar L÷ffler Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG184.34%3 066
JOHNSON & JOHNSON4.04%431 043
ROCHE HOLDING AG14.74%335 888
NOVO NORDISK A/S59.43%242 507
PFIZER, INC.18.34%240 919
ELI LILLY AND COMPANY48.17%226 799